263 related articles for article (PubMed ID: 25515506)
1. Editorial. Bioactivation of drugs: enzymes, reactive metabolites and adverse reactions.
Orhan H
Curr Med Chem; 2015; 22(4):406-7. PubMed ID: 25515506
[No Abstract] [Full Text] [Related]
2. Metabolic activation in drug-induced liver injury.
Leung L; Kalgutkar AS; Obach RS
Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
[TBL] [Abstract][Full Text] [Related]
3. Drugs and the liver.
Reidenberg MM; Breckenridge A
Clin Pharmacol Ther; 1998 Oct; 64(4):353-4. PubMed ID: 9797790
[No Abstract] [Full Text] [Related]
4. Cytochrome P450s and other enzymes in drug metabolism and toxicity.
Guengerich FP
AAPS J; 2006 Mar; 8(1):E101-11. PubMed ID: 16584116
[TBL] [Abstract][Full Text] [Related]
5. Are chemically reactive metabolites responsible for adverse reactions to drugs?
Williams DP; Kitteringham NR; Naisbitt DJ; Pirmohamed M; Smith DA; Park BK
Curr Drug Metab; 2002 Aug; 3(4):351-66. PubMed ID: 12093355
[TBL] [Abstract][Full Text] [Related]
6. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
Tang W; Lu AY
Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
[TBL] [Abstract][Full Text] [Related]
7. Non-cytochrome P450-mediated bioactivation and its toxicological relevance.
Gan J; Ma S; Zhang D
Drug Metab Rev; 2016 Nov; 48(4):473-501. PubMed ID: 27533622
[TBL] [Abstract][Full Text] [Related]
8. Bioactivation of drugs: risk and drug design.
Walsh JS; Miwa GT
Annu Rev Pharmacol Toxicol; 2011; 51():145-67. PubMed ID: 21210745
[TBL] [Abstract][Full Text] [Related]
9. Reactions and enzymes in the metabolism of drugs and other xenobiotics.
Testa B; Pedretti A; Vistoli G
Drug Discov Today; 2012 Jun; 17(11-12):549-60. PubMed ID: 22305937
[TBL] [Abstract][Full Text] [Related]
10. Impact of modeling and simulation: myth or fact?
Allerheiligen SR
Clin Pharmacol Ther; 2014 Oct; 96(4):413-5. PubMed ID: 25236663
[No Abstract] [Full Text] [Related]
11. Extrahepatic targets and cellular reactivity of drug metabolites.
Orhan H
Curr Med Chem; 2015; 22(4):408-37. PubMed ID: 25174932
[TBL] [Abstract][Full Text] [Related]
12. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
Grillo MP
Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
[TBL] [Abstract][Full Text] [Related]
13. Managing the liabilities arising from structural alerts: a safe philosophy for medicinal chemists.
Edwards PJ; Sturino C
Curr Med Chem; 2011; 18(20):3116-35. PubMed ID: 21651480
[TBL] [Abstract][Full Text] [Related]
14. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
Zhou S; Chan E; Duan W; Huang M; Chen YZ
Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
[TBL] [Abstract][Full Text] [Related]
15. Effective Application of Metabolite Profiling in Drug Design and Discovery.
Cerny MA; Kalgutkar AS; Obach RS; Sharma R; Spracklin DK; Walker GS
J Med Chem; 2020 Jun; 63(12):6387-6406. PubMed ID: 32097005
[TBL] [Abstract][Full Text] [Related]
16. Designing around Structural Alerts in Drug Discovery.
Kalgutkar AS
J Med Chem; 2020 Jun; 63(12):6276-6302. PubMed ID: 31497963
[TBL] [Abstract][Full Text] [Related]
17. Predicting toxicities of reactive metabolite-positive drug candidates.
Kalgutkar AS; Dalvie D
Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
[TBL] [Abstract][Full Text] [Related]
18. Drugs in liver disease.
Branch RA
Clin Pharmacol Ther; 1998 Oct; 64(4):462-5. PubMed ID: 9797803
[No Abstract] [Full Text] [Related]
19. [Gastrointestinal and hepatic side effects of drugs].
Meier PJ; Fricker R
Ther Umsch; 1987 Dec; 44(12):960-7. PubMed ID: 3327190
[No Abstract] [Full Text] [Related]
20. Practical approaches to resolving reactive metabolite liabilities in early discovery.
Dalvie D; Kalgutkar AS; Chen W
Drug Metab Rev; 2015 Feb; 47(1):56-70. PubMed ID: 25410913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
